Ultramicronized palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit : involvement of CB 1 receptors and TRPV 1 1

[1]  R. Capasso,et al.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent , 2015, British journal of pharmacology.

[2]  L. Facci,et al.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain , 2014, Inflammopharmacology.

[3]  Shu-Cheng Zhang,et al.  Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation , 2014, Journal of gastroenterology and hepatology.

[4]  R. Cuomo,et al.  Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation , 2013, Gut.

[5]  R. Capasso,et al.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis , 2013, British journal of pharmacology.

[6]  C. Russo,et al.  Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide , 2013, British journal of pharmacology.

[7]  K. Verhoeckx,et al.  Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. , 2013, CNS & neurological disorders drug targets.

[8]  H. Herzog,et al.  A role for neuropeptide Y in the gender‐specific gastrointestinal, corticosterone and feeding responses to stress , 2012, British journal of pharmacology.

[9]  E. Mazzon,et al.  Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia‐reperfusion in mice , 2012, Journal of leukocyte biology.

[10]  R. Capasso,et al.  Inhibitory effect of cannabichromene, a major non‐psychotropic cannabinoid extracted from Cannabis sativa, on inflammation‐induced hypermotility in mice , 2012, British journal of pharmacology.

[11]  J. Fichna,et al.  Brain-Gut Interactions in IBS , 2012, Front. Pharmacol..

[12]  E. Mazzon,et al.  Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α , 2012, Journal of Neuroinflammation.

[13]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[14]  P. Holzer.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system , 2011, Pharmacology & therapeutics.

[15]  J. Tack,et al.  TRP channels in neurogastroenterology: opportunities for therapeutic intervention , 2011, British journal of pharmacology.

[16]  M. D'Andrea,et al.  Small Intestinal Cannabinoid Receptor Changes Following a Single Colonic Insult with Oil of Mustard in Mice , 2010, Front. Pharmacol..

[17]  R. Abalo,et al.  The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212‐2 on gastrointestinal motility in the rat , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[18]  T. Bisogno,et al.  The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis , 2009, Proceedings of the National Academy of Sciences.

[19]  D. Piomelli,et al.  The identification of peroxisome proliferator‐activated receptor alpha‐independent effects of oleoylethanolamide on intestinal transit in mice , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  M. Cascio,et al.  Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis‐induced hypermotility: cross‐talk between κ‐opioid and cannabinoid CB1 receptors , 2008, British journal of pharmacology.

[21]  R. Capasso,et al.  The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high‐fat diet , 2008, British journal of pharmacology.

[22]  R. Capasso,et al.  Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies , 2005, Neuropharmacology.

[23]  R. Spiller.  Infection, immune function, and functional gut disorders. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  E. García-Nicas,et al.  A new model of visceral pain and referred hyperalgesia in the mouse , 2001, PAIN®.

[25]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[26]  U. Voss,et al.  Treatment of irritable bowel syndrome: sex and gender specific aspects. , 2012, Handbook of experimental pharmacology.

[27]  G. Astarita,et al.  The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. , 2005, Molecular pharmacology.

[28]  A. Izzo,et al.  Cannabinoids and the digestive tract. , 2005, Handbook of experimental pharmacology.